Price T Rowe Associates Inc G1 Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.2 - $4.98 $35,149 - $79,565	15,977 Added 89.99%	33,732 $77,000
Q1 2023 May 15, 2023	SELL	$2.57 - $8.16 $76,172 - $241,854	-29,639 Reduced 62.54%	17,755 $48,000
Q4 2022 Feb 14, 2023	SELL	$5.19 - $13.5 $1,925 - $5,008	-371 Reduced 0.78%	47,394 $257,000
Q2 2022 Aug 15, 2022	SELL	$4.04 - $8.51 $514,938 - $1.08 Million	-127,460 Reduced 72.74%	47,765 $236,000
Q1 2022 May 16, 2022	SELL	$7.6 - $11.02 $5.01 Million - $7.26 Million	-659,202 Reduced 79.0%	175,225 $1.33 Million
Q4 2021 Feb 14, 2022	BUY	$10.16 - $16.17 $108,559 - $172,776	10,685 Added 1.3%	834,427 $8.52 Million
Q3 2021 Nov 15, 2021	SELL	$13.16 - $22.47 $50,626 - $86,442	-3,847 Reduced 0.46%	823,742 $11.1 Million
Q2 2021 Aug 16, 2021	SELL	$19.57 - $26.32 $15.1 Million - $20.3 Million	-771,259 Reduced 48.24%	827,589 $18.2 Million
Q1 2021 May 17, 2021	BUY	$17.58 - $32.59 $842,750 - $1.56 Million	47,938 Added 3.09%	1,598,848 $38.5 Million
Q4 2020 Feb 16, 2021	BUY	$10.99 - $20.4 $17 Million - $31.6 Million	1,550,910 New	1,550,910 $27.9 Million

3.55M

11.7K

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.